Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR He...
29 Agosto 2018 - 1:00PM
Asterias Biotherapeutics, Inc. (NYSE American: AST), a
biotechnology company dedicated to developing cell-based
therapeutics to treat neurological conditions associated with
demyelination and cellular immunotherapies to treat cancer, today
announced that Michael Mulroy, President and Chief Executive
Officer, will participate in a panel discussion at the B. Riley FBR
Healthcare Conference at 8:20am ET/5:20 am PT on Tuesday, September
4, 2018 in New York.
The discussion will be moderated by George
Zavoico, Senior Research Analyst, SVP Equity Research, B. Riley FBR
and the other panelists will include senior executives from other
regenerative medicine therapies companies.
Mr. Mulroy will be meeting with investors
throughout the conference and one-on-one meetings may be scheduled
through the B. Riley 1x1 desk or by contacting Michael Polyviou, at
732-933-2754 or mpolyviou@evcgroup.com.
About Asterias
Biotherapeutics
Asterias Biotherapeutics, Inc. is a
biotechnology company dedicated to developing cell-based
therapeutics to treat neurological conditions associated with
demyelination and cellular immunotherapies to treat cancer.
Asterias is presently focused on advancing three clinical-stage
programs which have the potential to address areas of very high
unmet medical need in the fields of neurology and oncology.
AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase
1/2a dose escalation clinical trial in spinal cord injury. AST-VAC2
(antigen-presenting allogeneic dendritic cells) is an allogeneic
cancer immunotherapy. The company's research partner, Cancer
Research UK, has commenced a first-in-human clinical trial of
AST-VAC2 in non-small cell lung cancer. AST-VAC1
(antigen-presenting autologous dendritic cells) is an autologous
cancer immunotherapy with promising efficacy and safety data from
an earlier Phase 2 study in Acute Myeloid Leukemia (AML).
Asterias is also sponsoring pre-clinical work in two conditions
with a demyelinating component: Multiple Sclerosis and White Matter
Stroke, and is evaluating other cancer indications where its
immunotherapy platform could provide therapeutic benefit.
Additional information about Asterias can be found at
www.asteriasbiotherapeutics.com.
Contacts:Investor
Relations(510) 456-3892InvestorRelations@asteriasbio.comorEVC
Group, Inc.Michael Polyviou/Todd Kehrli(732)
933-2754mpolyviou@evcgroup.com; tkehrli@evcgroup.com
Grafico Azioni Asterias Biotherapeutics, Inc. (AMEX:AST)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Asterias Biotherapeutics, Inc. (AMEX:AST)
Storico
Da Set 2023 a Set 2024
Notizie in Tempo Reale relative a Asterias Biotherapeutics Common Series A (Borsa Americana (AMEX)): 0 articoli recenti
Più Articoli Notizie